Skip to main content

Table 1 Assessment of T-cell responses to the STEAP281-296 and EZH295-109-peptides in lung cancer patients and healthy donors.

From: Six-transmembrane epithelial antigen of the prostate and enhancer of zeste homolog 2 as immunotherapeutic targets for lung cancer

No.

Sex

Age (y)

Pathological stage

Histological diagnosis

No antigen (IFN-γ, pg/ml)

No antigen (GM-CSF, pg/ml)

STEAP281-296 (IFN-γ, pg/ml)

STEAP281-296 (GM-CSF, pg/ml)

EZH295-109 (IFN-γ, pg/ml)

EZH295-109 (GM-CSF, pg/ml)

TT830-843 (IFN-γ, pg/ml)

TT830-843 (GM-CSF, pg/ml)

1

F

61

M1a IV

adenocarcinoma

<

<

259.7 ± 74.6

749.4 ± 196.9

220.8 ± 175.3

968.5 ± 159.7

95.9 ± 9.2

545.7 ± 25.3

2

M

80

T3N0M0 IIB

adenosquamous carcinoma

<

<

320.5 ± 267.2

893.0 ± 355.6

565.7 ± 38.0

997.3 ± 27.4

985.1 ± 799.0

1267.8 ± 260.9

3

F

71

T1aN0M0 IA

adenocarcinoma

41.0 ± 5.0

35.8 ± 2.5

704.3 ± 502.5

516.0 ± 87.1

1030.0 ± 106.6

147.4 ± 55.7

1004.4 ± 451.3

620.8 ± 472.2

4

M

81

T3N0M0 IIB

adenocarcinoma

<

<

516.8 ± 0

206.0 ± 93.9

94.9 ± 0

65.9 ± 32.3

57.1 ± 25.1

77.9 ± 12.7

5

M

74

T1bN0M0 IA

adenocarcinoma

<

<

31.1 ± 0

135.4 ± 0

31.1 ± 20.1

34.8 ± 0

64.2 ± 0

31.2 ± 0

6

F

69

T3N0M0 IIB

adenocarcinoma

<

<

487.6 ± 444.3

474.9 ± 188.5

473.1 ± 354.0

389.3 ± 70.1

550.3 ± 118.1

917.4 ± 147.4

7

M

74

T2aN0M0 IB

basaloid carcinoma

<

<

189.7 ± 76.9

<

152.7 ± 57.5

<

203.9 ± 0

299.7 ± 278.1

8

M

71

T1aN0M0 IA

adenocarcinoma

<

<

173.7 ± 7.3

105.2 ± 49.9

54.3 ± 2.7

158.4 ± 56.7

91.4 ± 62.1

180.8 ± 1.7

9

F

56

T2aN0M0 IB

adenocarcinoma

<

<

<

<

134.7 ± 0

<

91.9 ± 0

<

10

F

60

T1aN1M0 IIA

adenocarcinoma

<

<

<

43.0 ± 38.3

44.2 ± 5.0

287.9 ± 337.1

234.3 ± 91.3

172.3 ± 58.3

11

M

32

-

-

<

<

<

440.6 ± 110.0

<

598.9 ± 105.1

<

301.8 ± 52.2

12

M

44

-

-

<

<

214.3 ± 50.6

122.5 ± 20.9

148.2 ± 18.1

<

492.7 ± 312.7

156.7 ± 39.0

13

M

38

-

-

<

<

180.1 ± 45.5

319.6 ± 64.7

190.4 ± 40.2

334.2 ± 57.1

246.8 ± 81.0

414.4 ± 115.1

  1. <: less than the lower limit of detection (mean < 30 pg/ml). No. 1 to 10 are lung cancer patients and No. 11 to 13 are healthy donors. IL-4, Il-5, IL-17, and IL-10 are not detected in all patients and healthy donors.
  2. IFN-γ and GM-CSF productions of all above cases were inhibited by anti-HLA-DR mAb L243 (mean < 30 pg/ml).